With two deals focused on its early-stage pipeline, AbbVie has extended its drug development collaboration with Calico and entered into a partnership with the California Institute for Biomedical Research (Calibr). The Calico deal has been extended for three more years in which the companies will commit an additional US$500 M each to continue research into oncology and neurological diseases. In the other deal, AbbVie and Calibr will research and develop next generation T-cell therapies targeted towards solid tumours. The agreement grants AbbVie access to Calibr’s switchable chimeric antigen receptor (CAR)-T platform.